Aligning biopharma and academic partnerships to advance drug delivery technologies: insights from a multidisciplinary panel.

The field of drug delivery is undergoing rapid transformation, driven by advances in biotherapeutics, new modalities, and innovative delivery technologies. However, translating these scientific breakthroughs into patient-centric therapies requires overcoming significant scientific, translational, and organizational barriers. This perspective piece provides insights from a multidisciplinary panel of leaders in biopharma, academia, and start-up innovation, focusing on the most promising opportunities and persistent challenges in the field. The discussion highlights the renewed and increased focus on subcutaneous and microneedle-based delivery systems, the evolving role of nanoparticle delivery, and the importance of aligning research with clinical and market needs through early cross-sector collaboration. The panel underscored the need for early stakeholder engagement, transparent communication, and iterative feedback to integrate business case considerations from the outset and foster successful partnerships. Various collaborative models that include pre-competitive consortia, open innovation incubators, public-private partnerships, and entrepreneurial training, are discussed for their effectiveness in bridging the gap between academic discovery and clinical translation. Ultimately, the advancement of drug delivery depends on multidisciplinary collaboration, robust translational frameworks, and sustained investment in innovative, patient-focused solutions that address real-world needs and improve patient outcomes.